Peter Johnson
← Back to University of Southampton
University of Southampton
Peter Johnson works in Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Reproductive System and Pregnancy, Viral-associated cancers and disorders, T-cell and B-cell Immunology. Recorded institutional associations include Cancer Research UK, University Hospital Southampton NHS Foundation Trust, NIHR CRUK Experimental Cancer Medicine Centre.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
2013 · 1,682 citationsDiffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015 · 930 citationsRituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
1998 · 893 citationsAdapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
2016 · 818 citationsResults of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
2015 · 762 citationsChemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
2016 · 615 citationsRandomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
2019 · 608 citationsRituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
2013 · 561 citationsRecombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
1993 · 543 citationsLiving risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study
2020 · 539 citationsEuropean Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma
2000 · 472 citationsLong-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
2015 · 410 citationsWhole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
2017 · 391 citationsComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
2003 · 390 citationsNivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
2019 · 353 citationsMarginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2020 · 350 citationsConcordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
2010 · 348 citationsPatterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.
1995 · 337 citationsDose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
2021 · 337 citationsAntigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
2010 · 335 citationsRisk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
2021 · 308 citationsMolecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
2018 · 300 citationsClinical trials of antibody therapy
2000 · 288 citationsMechanism of action of rituximab
2002 · 287 citationsValidation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling
2008 · 284 citations
